TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 10/27/20

Company’s Thin Film Freezing dry powder was equivalent to the liquid universal influenza formulated vaccine in preclinical immunogenicity and efficacy testing TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing an...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has expanded its engagement with one of its...

TFF Pharmaceuticals ([[TFFP]] +3.1%) has completed the single ascending dosing of three cohorts of healthy subjects for its second clinical program, tacrolimus inhalation powder for the prevention of lung transplant rejection.This 64-subject Phase 1 study will assess the safety, tolerabi...

Company completes dosing of three cohorts with Tacrolimus Inhalation Powder for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection Single ascending dose cohorts to date shown to be safe with no clinically significant ...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the results from its Annual Meeting of Stockholders...

IRISYS LLC Signs a Third Contract with TFF Pharma to Produce Medication to Treat Lung Conditions, Including COVID-19 PR Newswire SAN DIEGO, Sept. 30, 2020 SAN DIEGO , Sept. 30, 2020 /PRNewswire/ -- IRISYS LLC , a pharmaceutical contract manufacturing and ...

Scientists at the University of Texas at Austin report new pharmacokinetics data from the use of Thin Film Freezing technology to deliver remdesivir through dry powder inhalation Dry powder formulation of remdesivir with leucine found to allow more sustained release of remdesi...

Topline results from a Phase 1 clinical trial evaluating TFF Pharmaceuticals' ( TFFP +3.4% ) voriconazole inhalation powder in 64 healthy volunteers showed a favorable safety profile with no signs of clinically significant hepatic oar visual toxicities associated with oral or intraven...

TFF Pharmaceuticals ( TFFP +3.3% ) announces positive topline safety data from its Phase 1 trial of voriconazole inhalation powder, in 64 healthy volunteers. More news on: TFF Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Phase 1 Dosing of Voriconazole Inhalation Powder up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis (IPA) Phase 2 studies to commence, assessing the efficacy of the dry powder formulation for the treatment of IPA ...